Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multi-kinase inhibitors (e.g., sorafenib, regorafenib, neratinib) are used in cancer treatment.
• Combinatorial therapies are being explored to enhance efficacy and overcome resistance.

Purpose of the Study:

• To investigate the effects of combining multi-kinase inhibitors with other agents (HDAC inhibitors, pemetrexed, PDE5 inhibitors) in pre-clinical cancer models.
• To elucidate the molecular mechanisms underlying tumor cell death induced by these combinations.
• To identify resistance mechanisms and inform the development of future clinical trials.

Main Methods:

• Utilized pre-clinical models and patient data from Massey Cancer Center.
• Administered combinations of multi-kinase inhibitors with HDAC inhibitors, pemetrexed, or PDE5 inhibitors.
• Analyzed signaling pathways including ATM-AMPK-ULK-1, growth factor receptors, RAS, ERK1/2, AKT, mTOR, and p70 S6K.
• Assessed endoplasmic reticulum stress, autophagy, and mitochondrial dysfunction.

Main Results:

• Drug combinations enhanced ATM-AMPK-ULK-1 signaling and suppressed growth factor receptor and RAS signaling.
• Observed reduced protein synthesis, ER stress, and induced autophagic flux.
• Demonstrated tumor cell death via mitochondrial dysfunction, cytochrome c and AIF release.
• Identified evolutionary resistance mechanisms to two-drug combinations.

Conclusions:

• Multi-drug combinations show promise in inducing tumor cell death through complex molecular pathways.
• Understanding resistance mechanisms is crucial for developing more effective three-drug regimens.
• Translational pre-clinical research is vital for advancing cancer therapy.